PMID- 36314881
OWN - NLM
STAT- MEDLINE
DCOM- 20230110
LR  - 20230210
IS  - 1461-7285 (Electronic)
IS  - 0269-8811 (Linking)
VI  - 37
IP  - 1
DP  - 2023 Jan
TI  - Race and ethnicity moderate the associations between lifetime psychedelic use 
      (MDMA/ecstasy and psilocybin) and major depressive episodes.
PG  - 61-69
LID - 10.1177/02698811221127304 [doi]
AB  - BACKGROUND: Psychedelics are receiving renewed attention within Western medicine 
      as they represent potential treatments for many difficult-to-treat mental health 
      disorders. However, psychedelic science is limited in its focus and inclusion of 
      racial and ethnic minorities. Hence, this study examines whether race and 
      ethnicity moderate the associations that naturalistic 
      3,4-methylenedioxymethamphetamine (MDMA)/ecstasy use and psilocybin use share 
      with major depressive episodes (MDEs). METHOD: Data for this project are from The 
      National Survey on Drug Use and Health (2005-2019). Participants were adults aged 
      18 years and older (unweighted N = 596,187). This study used multivariable 
      logistic regression to test the interaction between race and ethnicity and 
      MDMA/ecstasy use and psilocybin use for predicting lifetime, past year, and past 
      year severe MDEs. RESULTS: Race and ethnicity significantly moderated the 
      associations between MDMA/ecstasy use and psilocybin use and MDEs. For White 
      participants, MDMA/ecstasy use and psilocybin use each were associated with 
      lowered odds of all three MDE outcomes (adjusted odds ratio (aOR) range: 
      0.82-0.92). For Hispanic participants, MDMA/ecstasy use and psilocybin use each 
      conferred lowered odds of only a past year MDE (MDMA/ecstasy aOR: 0.82; 
      psilocybin aOR: 0.79). For Non-Hispanic Racial Minority participants, 
      MDMA/ecstasy and psilocybin use did not confer lowered odds of any MDE outcomes. 
      CONCLUSION: Race and ethnicity have an impact on the associations that 
      psychedelics share with mental health outcomes. Future research should explore 
      the impact of identity and discrimination on the effects of psychedelics and 
      should explore whether these substances can serve as effective treatments for 
      minorities when used in culturally informed contexts.
FAU - Jones, Grant M
AU  - Jones GM
AUID- ORCID: 0000-0002-2426-310X
AD  - Department of Psychology, Harvard University, Cambridge, MA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221031
PL  - United States
TA  - J Psychopharmacol
JT  - Journal of psychopharmacology (Oxford, England)
JID - 8907828
RN  - 2RV7212BP0 (Psilocybin)
RN  - 0 (Hallucinogens)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Psilocybin/pharmacology
MH  - *Hallucinogens/pharmacology
MH  - *N-Methyl-3,4-methylenedioxyamphetamine/therapeutic use
MH  - Ethnicity
MH  - *Depressive Disorder, Major/drug therapy
OTO - NOTNLM
OT  - NSDUH
OT  - psychedelics
OT  - race
EDAT- 2022/11/01 06:00
MHDA- 2023/01/11 06:00
CRDT- 2022/10/31 09:23
PHST- 2022/11/01 06:00 [pubmed]
PHST- 2023/01/11 06:00 [medline]
PHST- 2022/10/31 09:23 [entrez]
AID - 10.1177/02698811221127304 [doi]
PST - ppublish
SO  - J Psychopharmacol. 2023 Jan;37(1):61-69. doi: 10.1177/02698811221127304. Epub 
      2022 Oct 31.